

Nebivolol

Catalog No: tcsc2141



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

118457-14-0

Formula:

$C_{22}H_{25}F_2NO_4$

Pathway:

GPCR/G Protein

Target:

Adrenergic Receptor

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

R 065824

Observed Molecular Weight:

405.44


Product Description

Nebivolol selectively inhibits β_1 -adrenergic receptor with IC₅₀ of 0.8 nM.

Target: β_1 -adrenergic receptor

Nebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent manner. Nebivolol treatment for 7 days causes significant reduction in cell growth of haCSMCs with IC₅₀ of 6.1 μ M, and inhibits accelerated haCSMC proliferation stimulated by growth factors PDGF-BB, bFGF, and TGF β with IC₅₀ values of 6.8 μ M, 6.4 μ M and 7.7 μ M, respectively. Nebivolol treatment (10⁻⁵ M) of haCSMCs for 48 hours induces a moderate apoptosis of 23% and a decrease from 16% to 5% in the number of cells in S-phase. During Nebivolol incubation, NO formation of HaCEs increases, while endothelin-1 transcription and secretion are suppressed.

Administration of Nebivolol (initially by iv within 10 minutes of reperfusion and then orally) to rats with myocardial infarction (MI) reduces myocardial apoptosis, which is mediated by regulation of NO. Nebivolol, significantly, prevents left ventricular (LV) pressure changes, reduces total and regional apoptotic cardiomyocytes. Nebivolol treatment lowers mean blood pressure (MBP) in rats with MI slightly, but not significantly.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!